Fig. 5: ATUX-1215 or ATUX-5800 treatment alters phosphorylation state of RNA Polymerase II C terminal domain (R Pol II CTD). | Cell Death & Disease

Fig. 5: ATUX-1215 or ATUX-5800 treatment alters phosphorylation state of RNA Polymerase II C terminal domain (R Pol II CTD).

From: PP2A activation targets MYCN in neuroblastoma

Fig. 5

a–c SK-N-AS, SK-N-BE(2), and COA3 (1 × 106 cells) were treated with increasing concentrations of ATUX-1215 or ATUX-5800 (SK-N-AS or SK-N-BE(2), 0–20 μM, 24 h; COA3, 0–8 μM, 72 h) and expression of total R Pol and phosphorylation at S5 was detected using immunoblotting. In SK-N-AS cells, decreased phosphorylation of R Pol S5 was noted only at the 20 μM concentration of ATUX-1215 (a, left panel). In SK-N-BE(2) cells, R Pol phosphorylation at S5 was decreased following 20 μM ATUX-1215 treatment (b, left panels), and ATUX-5800 reduced phosphorylation of R Pol at S5 at both concentrations (b, right panels). Phosphorylation of R Pol S5 was decreased by both compounds in the COA3 cells (c). β-actin or GAPDH served as loading controls.

Back to article page